Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Sloan Ratio % : 0.00% (As of Dec. 2023)

Sichuan Kelun-Biotech Biopharmaceutical Co Sloan Ratio % Chart

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's Sloan Ratio %

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Sloan Ratio % falls into.

Sichuan Kelun-Biotech Biopharmaceutical Co Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Sichuan Kelun-Biotech Biopharmaceutical Co's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sichuan Kelun-Biotech Biopharmaceutical Co's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sichuan Kelun-Biotech Biopharmaceutical Co's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -56.316 (Sep. 2022 ) + -329.289 (Dec. 2022 ) + 0 (Jun. 2023 ) + 0 (Dec. 2023 ) = HK$-385.6 Mil.
Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 122.851 (Sep. 2022 ) + -252.01 (Dec. 2022 ) + 0 (Jun. 2023 ) + 0 (Dec. 2023 ) = HK$-129.2 Mil.
Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -189.929 (Sep. 2022 ) + 156.8 (Dec. 2022 ) + 0 (Jun. 2023 ) + 0 (Dec. 2023 ) = HK$-33.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Sichuan Kelun-Biotech Biopharmaceutical Co has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

Sichuan Kelun-Biotech Biopharmaceutical Co Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description